30th week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130190343 | COMPOSITIONS AND METHODS FOR MINIMIZING OR REVERSING AGONIST-INDUCED DESENSITIZATION - Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder. | 2013-07-25 |
20130190344 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-25 |
20130190345 | MATRINIC ACID/MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF - The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS. | 2013-07-25 |
20130190346 | METHOD OF REDUCING CNS AND GASTROINTESTINAL SIDE AFFECTS ASSOCIATED WITH LONG-TERM, DEXTROMETHORPHAN/LOW-DOSE QUINIDINE COMBINATION THERAPY - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy. | 2013-07-25 |
20130190347 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF - This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-25 |
20130190348 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF - This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-25 |
20130190349 | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF ZOLPIDEM - The invention provides sprayable aqueous compositions containing zolpidem or single stereoisomer, mixtures of stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, a solubilizing agent, a water soluble polymer with bioadhesive property. When administered intranasally using a spray device, zolpidem is rapidly absorbed with prolonged intranasal residence time and improved bioavailability. The compositions can be applied for the treatment of insomnia-related disorders such as difficulties with sleep initiation or middle of the night awakenings. | 2013-07-25 |
20130190350 | Mediators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto - The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. | 2013-07-25 |
20130190351 | BICYCLIC AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES - This invention relates to bicyclic amide compounds, pharmaceutical compositions and methods for use in the prevention and treatment of a variety of conditions and/or disease states including cerebral insufficiency, through the enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors as defined herein. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in other disorders wherein a deficiency in neurotrophic factors is implicated, as well as other disorders as described herein. | 2013-07-25 |
20130190352 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN - Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain. | 2013-07-25 |
20130190353 | FUNGICIDE COMPOSITION COMPRISING A TETRAZOLYLOXIME DERIVATIVE AND A THIAZOLYLPIPERIDINE DERIVATIVE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative and a thiazolylpiperidine derivative, which may further comprise another fungicide and/or an insecticide active substance or compound. | 2013-07-25 |
20130190354 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR - The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, one or more surfactants with lubricant properties, one or more dry binders with disintegrant properties, one or more fillers and one or more disintegrants. | 2013-07-25 |
20130190355 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I - Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC | 2013-07-25 |
20130190356 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS - Compounds of the formula I: | 2013-07-25 |
20130190357 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING A PRECURSOR LESION AND/OR ESOPHAGEAL CANCER - One aspect of the present disclosure relates to a method for predicting a subject's risk of developing an esophageal cancer, a precursor lesion, or both. One step of the method includes obtaining a biological sample from the subject. Next, the presence of at least one germline mutation is determined in the biological sample. The subject is at an increased risk of an esophageal cancer, a precursor lesion, or both, where the presence of at least one germline mutation is determined. | 2013-07-25 |
20130190358 | NOVEL ORALLY ADMINISTERED DABIGATRAN FORMULATION - The invention relates to a new medicament formulation of the active substance dabigatran etexilate of formula I | 2013-07-25 |
20130190359 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE - This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2013-07-25 |
20130190360 | Compositions Containing a Pyripyropene Insecticide and an Adjuvant - Pesticidal composition containing a pyripyropene insecticide and an adjuvant | 2013-07-25 |
20130190361 | SUBSTITUTED OXADIAZOLE COMPOUNDS - Disclosed are compounds of Formula (I): | 2013-07-25 |
20130190362 | ARTHROPODICIDAL ANTHRANILAMIDES - This invention provides a composition comprising a biologically effective amount of a compound of Formula 1, an N-oxide or an agriculturally suitable salt thereof | 2013-07-25 |
20130190363 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES - An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient. | 2013-07-25 |
20130190364 | PEST CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PEST - The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more diamide compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of a compound of Formula (2): wherein a combination of R | 2013-07-25 |
20130190365 | Use of Deferiprone and Methods to Treat and/or Prevent Friedreich Ataxia Resulting from Intracellular Mishandling of Iron - A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron. | 2013-07-25 |
20130190366 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF - Substantially pure salts of febuxostat of Formula (IA): wherein Y is Na | 2013-07-25 |
20130190367 | FLUORINATED THIAZOLES FOR USE IN TREATING CANCER - Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R | 2013-07-25 |
20130190368 | NOVEL POLYMORPHS OF FEBUXOSTAT - The present invention provides a novel 1,4-dioxane solvate form of febuxostat and process for its preparation. The present invention also provides novel crystalline forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them. | 2013-07-25 |
20130190369 | MODIFIED MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 2013-07-25 |
20130190370 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor - The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental. | 2013-07-25 |
20130190371 | Fungicide Active Substance Combinations - The novel active compound combinations comprising 2-[2-(1-chorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula | 2013-07-25 |
20130190372 | BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine. | 2013-07-25 |
20130190373 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS - A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment. | 2013-07-25 |
20130190374 | GRM3 MUTATIONS AND USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF MELANOMA - Described herein is a G-protein coupled receptor (GPCR)-directed mutational analysis of tumor DNA obtained from melanoma tissue samples. The GPCR gene glutamate receptor, metabotropic 3 (GRM3) was identified as the most highly mutated GPCR gene in this screen. Functional characterization of GRM3 mutants revealed that these mutants promote activation of MEK, anchorage-independent cell growth and metastasis. Thus, provided herein are methods of diagnosing a subject as having melanoma, or susceptible to developing melanoma, by detecting the presence of at least one mutation in GRM3. Also provided are methods of treating a subject with melanoma by detecting the presence of at least one mutation in GRM3 and administering an appropriate therapy. Further provided are methods of selecting a subject diagnosed with melanoma as a candidate for treatment with a GRM3 inhibitor, an MEK inhibitor, or both, by detecting the presence of at least one mutation in GRM3. | 2013-07-25 |
20130190375 | CARBOXAMIDES - Use of carboxamides of the formula (I) | 2013-07-25 |
20130190376 | METHODS OF USE OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides methods for treating a disease or condition by administering to a subject at a frequency of more than 24 hours between doses, compositions and formulations of compounds having formula (I), and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. | 2013-07-25 |
20130190377 | Novel Lactams - The present invention relates to novel lactams of formulae (I) and (II). The present invention further relates to the use of these compounds in the treatment of microbial infections and microbial contamination of surfaces, particularly infections and surface contaminations characterised by biofilm formation. Further provided are compounds of formula (I) and (II) substituted with acrylate or methacrylate groups and their attachment to surfaces or polymers to inhibit microbial contamination. | 2013-07-25 |
20130190378 | Imine substituted 2,4-diaryl-pyrroline derivatives as pesticides - The present invention relates to imine compounds which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds. | 2013-07-25 |
20130190379 | SMALL RNA MOLECULES, PRECURSORS THEREOF, MEANS AND METHODS FOR DETECTING THEM, AND USES THEREOF IN TYPING SAMPLES - The invention is related to small RNA molecules, precursors thereof and methods for detecting such molecules. The invention is in particular concerned with differentially expressed small RNA molecules and precursors thereof. Various collections of small RNA molecules, precursors thereof and collections of probe and primers that can be used to detect small RNA molecules, precursors thereof are provided. Further provided are diagnostic test based on this differential expression. Also provided are therapeutic applications using one or more of the members of the presented collections. | 2013-07-25 |
20130190380 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 2013-07-25 |
20130190381 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS - The present invention provides methods and compounds for treating viral infections using modulators of host cell enzymes relating to long chain fatty acid and lipid droplet metabolism. It includes a method of treating viral infections using triacsin C and its relatives, analogues and derivatives as well as other inhibitors of long chain fatty acid metabolism and lipid droplet metabolism. | 2013-07-25 |
20130190382 | METHODS FOR INHIBITING EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR - This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds. | 2013-07-25 |
20130190383 | NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF - This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA). The nucleic acid compounds are useful in various therapeutic modalities. | 2013-07-25 |
20130190384 | MODULATION OF FACTOR 11 EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | 2013-07-25 |
20130190385 | METHOD FOR MODULATING DOUBLE-STRAND BREAK-INDUCED HOMOLOGOUS RECOMBINATION - The present invention concerns a method for modulating double-strand break-induced homologous recombination through the identification of effectors that modulate said double-strand break-induced homologous recombination by uses of interfering agents; these agents are capable of modulating double-strand break-induced homologous recombination through their respective actions on said effectors. The present invention also concerns the uses of these effectors and interfering agents and derivatives, respectively, by introducing them in an eukaryotic cell in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency. The present invention also relates to specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency. | 2013-07-25 |
20130190386 | Breast Cancer Biomarker Signatures for Invasiveness and Prognosis - MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis. | 2013-07-25 |
20130190387 | TREATMENT OR PREVENTION OF OTO-PATHOLOGIES BY INHIBITION OF PRO-APOPTOTIC GENES - The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. | 2013-07-25 |
20130190388 | Methods and Compositions Related to DLK-1 and the P38 MAPK Pathway in Nerve Regeneration - Disclosed are compositions and methods for treating neurodegenerative disease. | 2013-07-25 |
20130190389 | Method For Producing Novel Hipsc By Means Of Mirna Introduction - A novel compound to induce a pluripotent stem cell is provided. A novel anti-malignant-tumor substance is provided. A pluripotent stem cell-inducing agent, including a single-stranded or double-stranded polynucleotide containing the base sequence shown in SEQ ID NO:41 or a base sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 41, in which the pluripotent stem cell-inducing agent induces a cell to become a pluripotent stem cell is provided. | 2013-07-25 |
20130190390 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD - Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy. | 2013-07-25 |
20130190391 | TRAVERSAL OF NUCLEIC ACID MOLECULES THROUGH A FLUID SPACE AND EXPRESSION IN REPAIR CELLS - Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest. | 2013-07-25 |
20130190392 | METHOD OF PREPARING SOY ISOFLAVONE NANOPARTICLES BY PRECIPITATION WITH COMPRESSED ANTISOLVENT (PCA) USING A SUPERCRITICAL FLUID - The present invention relates to a method of preparing a solid form of soy isoflavone (e.g. genistein). In particular, the present invention relates to a method of preparing a solid form of soy isoflavone by precipitation with compressed antisolvent using a supercritical fluid to produce nano-sized particles of soy isoflavone with an improved dissolution rate and bioavailability. An oral composition or aerosolized formulation comprising the nanoparticles of the soy isoflavone prepared by the method of the present invention is also disclosed herein. The dissolution rate and bioavailability of the nanoparticles of the soy isoflavone prepared by the method of the present invention have a 2-fold increase and a 2.6-fold increase respectively as compared to those of the raw soy isoflavone. | 2013-07-25 |
20130190393 | USES OF INCENSOLE, INCENSOLE ACETATE AND DERIVATIVES THEREOF - The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in cognitive function, and deterioration in neurobehavioral function. Pharmaceutical compositions and method of treatment, prevention or amelioration of the above-mentioned diseases or conditions are also provided. | 2013-07-25 |
20130190394 | Applications Of Arctigenin In Formulating Drugs For Preventing Or Treating Diseases Related To Red Blood Cell Reduction - Provided are applications of arctigenin in formulating medicines for preventing or treating diseases related to blood cell reduction, and preparations that contain arctigenin, particularly micro-emulsions that contain arctigenin. Experiments show that arctigenin can significantly increase the white cell counts after chemotherapy, especially the neutrophil granulocyte counts. | 2013-07-25 |
20130190395 | AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS - The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection. | 2013-07-25 |
20130190396 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH - Therapeutic ureido-sulfonamide compositions having compounds with the formula | 2013-07-25 |
20130190397 | NOVEL COMPOUND ACCELERATING SECRETION OF HUMAN-DERIVED ANTI-MICROBIAL PEPTIDE, METHOD FOR PREPARING SAME, AND COMPOSITION HAVING SAME AS ACTIVE INGREDIENT - Disclosed is a compound having an acceleration effect on the secretion of human β-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body. | 2013-07-25 |
20130190398 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 2013-07-25 |
20130190399 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) - The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor. | 2013-07-25 |
20130190400 | METHOD FOR PRODUCING GAMMA-AMINOBUTYRIC ACID AND FOOD PRODUCED THEREBY - The embodiment of invention provides a method for producing γ-aminobutyric acid, including the steps of providing a medium including | 2013-07-25 |
20130190401 | VETERINARY DERMATOLOGIC COMPOSITION - This invention relates to the use of an active compound selected from the group comprising a sphingoid base, a sphingoid base derivative or a mixture of two or more these compounds for manufacturing a cosmetic composition suitable for topical application with animals having an at least partly fur covered skin for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur. | 2013-07-25 |
20130190402 | Methods Of Treating Autism With mGluR5 Antagonists - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 2013-07-25 |
20130190403 | ADMINISTRATION OF INTRAVENOUS IBUPROFEN TO TRAUMA PATIENTS - A method for treating human patients who require hospitalization for a trauma injury wherein the patients are intravenously administered a first dose of a therapeutically effective dose of ibuprofen intravenously as soon as possible after hospitalization is disclosed. The patients are further treated with intravenous ibuprofen at suitable dosing intervals to the human patient until (a) the patient no longer requires intravenous dosing of ibuprofen. | 2013-07-25 |
20130190404 | CRYSTALS OF CARBOPROST TROMETHAMINE AND THE PREPARATION METHOD AS WELL AS THE USES THEREOF - Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has characteristic peaks in the X-ray diffraction pattern at the following 2θ angles: 6.6±0.2°, 9.9±0.2°, 18.5±0.2° and 20.1±0.2°. Furthermore, also disclosed are preparation method and the use of the crystal. | 2013-07-25 |
20130190405 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor. | 2013-07-25 |
20130190406 | PEST CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PEST - The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and the cyanamide compound represented by Formula (2) shows an excellent controlling activity on a pest. | 2013-07-25 |
20130190407 | CALCIUM RECEPTOR-ACTIVE MOLECULES - The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca | 2013-07-25 |
20130190408 | BIOCOMPATIBLE HYDROPHILIC COMPOSITIONS - Durable hydrophilic compositions comprising aliphatic polyester, an anionic surfactant, and in some embodiments, a carrier. | 2013-07-25 |
20130190409 | DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF - Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO | 2013-07-25 |
20130190410 | NOVEL POLYMERIC THICKENING AGENT FREE OF ACRYLAMIDE FRAGMENTS, METHOD FOR THE PREPARATION THEREOF, AND COMPOSITION CONTAINING SAME - A composition including an oil phase, an aqueous phase, at least one water-in-oil emulsifying system in the form of a positive latex, characterized in that the composition includes a straight, branched, or cross-linked anionic polyelectrolyte, including: a) a non-zero molar proportion of monomer units from acrylic acid in free or partially salified form; and b) a non-zero molar proportion of monomer units from the acid of formula (I): | 2013-07-25 |
20130190411 | ANDERSON-TYPE HETEROPOLY COMPOUND-BASED CATALYST COMPOSITIONS AND THEIR USE CONVERSION OF SYNTHESIS GAS TO OXYGENATES - Use a transition metal-containing, Anderson-type heteropoly compound catalyst to convert synthesis gas to an oxygenate, especially an alcohol that contains from one carbon atom to six carbon atoms. | 2013-07-25 |
20130190412 | FOAMABLE COMPOSITION FOR POLYURETHANE FOAM AND POLYURETHANE FOAM - A foamable composition for polyurethane foam is provided which advantageously improves heat insulating properties, a long-term stability, and a dimensional stability of a polyurethane foam that is produced by using carbon dioxide as a blowing agent. Further, a polyurethane foam which has excellent heat insulating properties is provided by foaming and curing the foamable composition for polyurethane. In the production of the polyurethane foam in which carbon dioxide is used in the foaming, a polyol component is used which includes a phenolic resin polyol that is obtained by adding at least one alkylene oxide to a phenolic novolak resin, and an aromatic amine polyol that is obtained by adding at least one alkylene oxide to an aromatic diamine such that the total amount thereof is 60% or more by mass, based on the total polyol component. | 2013-07-25 |
20130190413 | POLYSTYRENE/POLYETHYLENE OXIDE COPOLYMER CELL SIZE ENLARGER FOR FOAM - Polymeric foam and polymeric foam products that contain a foamable polymer material, at least one blowing agent, an infrared attenuating agent, and a polystyrene/polyethylene oxide copolymer are provided. In exemplary embodiments, the blowing agent contains an HFC. The maleic anhydride-styrene copolymer grafted with polyethylene oxide increases the cell size of the polymer foam and offsets or even negates the decreased cell size caused by an HFC blowing agent and/or infrared attenuating agents. In addition, the copolymer of maleic anhydride-styrene grafted with polyethylene oxide has a positive affect on the processability of the blowing agent(s) in the composition by both widening the process window and enhancing the solubility of the blowing agent in the polymer melt. Thus, the polystyrene/polyethylene oxide copolymer present in the inventive composition acts as a cell enlarger, a plasticizer, and a processing aid. A method of forming an extruded foam product is also provided. | 2013-07-25 |
20130190414 | ADDITIVE COMPOSITION USEFUL FOR CONTROLLING THE FOAM PROPERTIES IN THE PRODUCTION OF FLEXIBLE POLYURETHANE FOAMS CONTAINING POLYOLS BASED ON RENEWABLE RAW MATERIALS - The present invention relates to an additive composition useful as additive for controlling the foam properties of polyurethane foams which is characterized in that it contains at least one ionic surfactant A selected from those of formula A | 2013-07-25 |
20130190415 | Reduced Emissions Low Density Spray Polyurethane Foam - This disclosure is directed to make low density and low amine emissions water blown polyurethane foams using a reactive catalyst composition. The method is particularly useful in the preparation of full water blown, low density polyurethane foams having a density in the range of about 6 to about 16 kg/m3. A catalyst composition comprising at least one non-emissive amine catalyst and tetraalkyl guanidine, the method of employing the catalyst composition and a formulation comprising the catalyst composition are disclosed. | 2013-07-25 |
20130190416 | COMPOSITE MOLDED BODY AND METHOD FOR PRODUCING SAME - The present invention relates to a composite formed article, comprising a formed article (A) and a rubber- or gel-like cured product (B), wherein the rubber- or gel-like cured product (B) is obtained by curing an active energy ray-curable composition. The present invention also relates to a forming method for producing a composite formed article, comprising injecting the curable composition (C) into a cavity in the formed article (A) and then curing the curable composition (C) by exposure to active energy rays to give the rubber- or gel-like cured product (B). The method aims to provide a composite article that combines the functionalities of each material without deteriorating the shape or performance of either material in the composite article. | 2013-07-25 |
20130190417 | POLYMERIZABLE GEMINI DICARBOXLATE SURFACTANTS AND LYOTROPIC LIQUID CRYSTALS AND MEMBRANES MADE THEREFROM - The disclosure provides anionic Gemini surfactants comprising at least two carbonyl moieties and at least two aliphatic moieties. In some aspects, at least two of the aliphatic moieties comprise at least seven carbon atoms and at least one pair of conjugated carbon-to-carbon double bonds. The anionic Gemini surfactants are polymerizable and may be used to prepare triply periodic multiply continuous lyotropic phase and polymers thereof that substantially retain triply periodic multiply continuous lyotropic phase structure. | 2013-07-25 |
20130190418 | POLYETHERESTER POLYOLS AND PREPARATION THEREOF - The present invention relates to novel polyetherester polyols and to a process for preparation thereof. | 2013-07-25 |
20130190419 | PRODUCING RIGID POLYURETHANE FOAMS AND RIGID POLYISOCYANURATE FOAMS - Rigid polyurethane foams or rigid polyisocyanurate foams with low brittleness are produced by the reaction of polyisocyanate polyetherester polyols based on aromatic dicarboxylic acids obtained by esterification of a dicarboxylic acid composition containing aromatic dicarboxylic acids and aliphatic dicarboxylic acids, fatty acids, aliphatic or cycloaliphatic diols having 2 to 18 carbon atoms or alkoxylates thereof, and a polyether polyol having a functionality of not less than 2. | 2013-07-25 |
20130190420 | NONTEMPERATURE SENSITIVE MEMORY FOAM OF MDI SYSTEM SUITABLE FOR HORIZONTAL FOAMING PROCESS - A MDI system non-temperature sensitive memory sponge suitable for flat foam foaming process, is made by mainly using polyether polyol and polymer polyol as main material, then adding three additives isocyanate and foaming agent, the pore adjusting agent and catalyst. The polyether polyol is polyoxypropylene glycerol with molecular weight of 700, the polymer polyol is high activity grafting polyether, the isocyanate is modified polyphenyl methane diisocyanate, wherein a polyoxypropylene trihydroxy ether with the molecular weight of 4800 is added to the polyether polyol, polyol chain extender is added to said additives. | 2013-07-25 |
20130190421 | LOW ODOR ENVIRONMENTALLY-FRIENDLY NANO-PIGMENT INKJET INK COMPOSITION - A low odor environmentally-friendly nano-pigment inkjet ink composition has good storage stability, inkjet stability, and good print quality. The printhead nozzles are not easily clogged by such an inkjet ink composition. The printed image has high gloss, scratch resistance, and weather resistance. The inkjet ink composition using low toxic and low odor raw material has a high flash point, and has high security to human health and environment. The inkjet ink composition can meet both the environmental requirement and the print quality requirement. The inkjet ink composition includes 1-10% of N-ethyl pyrrolidone, 1-20% propylene carbonate, 50-80% glycol ether solvent, pigment, dispersant, resin, plasticizer, surfactant, and cyclic tertiary amine compound as an acidity regulator. | 2013-07-25 |
20130190422 | DENTAL COMPOSITION SUITABLE FOR GRINDING WITH AUTOMATIC GRINDING APPARATUS - Provided is a dental composition comprising a first largest group of particles and resin matrix, wherein the first largest group consists of particles whose particle size ranges from 0.7 to 1.5 times the representative particle size of the first largest fraction in a population of particles included in the composition whose particle size ranges from 110 to 1000 μm; and wherein the ratio of the number of particles included in the first largest group to the number of particles whose particle size ranges from 0.5 to 2.0 times the representative particle size of the first largest fraction is equal to or more than 0.8. | 2013-07-25 |
20130190423 | Rubber Compositions Including Metal Phosphate Esters - A composition includes a diene rubber and a metal phosphate ester of the formula: | 2013-07-25 |
20130190424 | MELAMINE EPOXY RESIN MONOMER AND RESIN COMPOSITION - A melamine epoxy resin monomer including: a glycidyl group; and a structural unit having a melamine residue and being represented by the following Formula (I) is disclosed. In Formula (I), each of R | 2013-07-25 |
20130190425 | POLYCARBONATE-POLYESTER COMPOSITIONS, METHODS OF MANUFACTURE, AND ARTICLES THEREOF - A composition comprising polycarbonate, polyethylene terephthalate, organopolysiloxane-polycarbonate block copolymer, and epoxy-functional block copolymer for providing an improved balance of properties, including heat aging performance in combination with impact resistance. Articles molded from the composition are advantageously useful for automotive applications. | 2013-07-25 |
20130190426 | RUBBER COMPOSITION FOR TIRE, AND PNEUMATIC TIRE - Provided are a rubber composition for a tire which makes it possible to improve the handling stability and fuel economy in a well-balanced manner by a simple method without requiring any chemical reaction process for surface treatment of microfibrillated plant fibers; and a pneumatic tire formed from the rubber composition. The rubber composition for a tire contains: a rubber component; microfibrillated plant fibers; a phenol resin; and a curing agent. It is preferable that the rubber component should include at least one selected from the group consisting of natural rubber, modified natural rubber, synthetic rubber, and modified synthetic rubber, and it is preferable that the microfibrillated plant fibers should be cellulose microfibrils. | 2013-07-25 |
20130190427 | RENEWABLE AND COST-EFFECTIVE FILLERS FOR POLYMERIC MATERIALS - Polymer composites are provided, and more particularly, polymer composites of ground date pits disposed in a polymer matrix. The composites can be formed by a process of preparing reinforced polymer composites having a fibril melt fracture surface, including blending a mixture of date pit particulate with a thermoplastic polymer; melting the mixture; and forcing the melt through a die to produce the polymer composite having a fibril containing surface. | 2013-07-25 |
20130190428 | Wood Composite Process Enhancement - Disclosed is a method of preparing a lignocellulosic composite; the method comprising the steps of combining one or more dry protein sources as powders and one or more lignocellulosic materials; subsequently combining with the protein and lignocellulosic combination, a liquid mixture comprising a curative for the protein source, forming the resulting mixture into a composite structure and then curing the composite structure. | 2013-07-25 |
20130190429 | Biodegradable Hydrophobic Cellulosic Substrates And Methods For Their Production Using Reactive Silanes - A method for rendering a substrate hydrophobic while maintaining its biodegradability includes treating the substrate with a reactive silane such that the reactive silane forms a resin in the interstitial spaces of the substrate. The method parameters are controlled such that the resulting hydrophobic cellulosic substrate is compostable. | 2013-07-25 |
20130190430 | SELF PRIMING SPACKLING COMPOUND - A self-priming spackling compound includes between about 35% by weight and about 65% by weight acrylic latex resin, between about 20% by weight and about 50% by weight filler material, and between about 1% by weight and about 20% by weight water. In certain aspects, the latex resin may have an average latex particle size of less than about 0.18 microns, a minimum film formation temperature of less than about 15 degrees Celsius, and/or a glass transition temperature (Tg) of less than about 25 degrees Celsius. To further enhance the self-priming performance of the spackling compound, the formulation may further comprise a colorant such as titanium dioxide. | 2013-07-25 |
20130190431 | Method for Dispersing and Aggregating Components of Mineral Slurries and Low Molecular Weight Multivalent Polymers for Mineral Aggregation - The disclosure relates generally to the use of low molecular weight polymers to aggregate mineral components in aqueous mineral slurries to release and separate individual components of the slurry, which may then be recovered from the slurry. | 2013-07-25 |
20130190432 | Flame Retardant-Stabilizer Combination For Thermoplastic Polymers - A novel flame retardant-stabilizer combination for thermoplastic polymers, comprising as component A 20 to 99% by weight of a dialkylphosphinic salt of the formula (I) and/or of a diphosphinic salt of the formula (II) and/or polymers thereof in which R | 2013-07-25 |
20130190433 | PROCESS OF FORMING AN ARAMID COPOLYMER - The invention concerns processes for forming a polymer comprising residues of 2-(4-amino phenyl)-5(6)amino phenyl benzimidazole (DAPBI), paraphenylene diamine (PPD), and terephthaloyl dichloride, comprising the steps of: (a) forming a slurry of DAPBI in a solvent system comprising an organic solvent and an inorganic salt; (b) adding less than a stoichiometric amount, relative to the amount of DAPBI, of terephthaloyl dichloride to the slurry; (c) agitating the slurry to react the DAPBI and terephthaloyl dichloride to form an oligomeric solution; (d) adding PPD to the oligomeric solution and agitating until essentially all of the PPD is dissolved, followed by the addition of terephthaloyl dichloride to form a prepolymer solution; and (e) allowing the prepolymer solution to form a polymer. | 2013-07-25 |
20130190434 | Polyolefin Compositions for Film, Fiber and Molded Articles - Polyolefin compositions prepared by processing a polyolefin resin and a mixture of a select hindered phenol and select liquid phosphite above the melting point of the polyolefin contain a higher amount of retained active phosphorus than when other common phosphites are used. The compositions, and films, fibers and other molded articles prepared from the compositions show improved stabilization against NOX discoloration and long term oxidation. The select liquid phosphite consists mainly of a mixture of triphenyl phosphite derivatives wherein the phenyl groups are substituted by different numbers of butyl and/or amyl substituents. | 2013-07-25 |
20130190435 | METHOD OF PREPARATION OF NUCLEATED SEMI-CRYSTALLINE POLYMER - The method of preparation of nucleated semi-crystalline polyolefin via coordination polymerization, wherein the nucleating agent is dosed in form of the suspension or the solution in a non-polar hydrocarbon solvent or in concentrated organoaluminum as part of the catalyst system for α-olefin polymerization. | 2013-07-25 |
20130190436 | ADHESIVE GROUT FOR PLASTER REHABILITATION - An adhesive grout for plaster rehabilitation. The grout formulation includes fluid petroleum coke, an acrylic resin, a pseudo-plastic thickener formed from an anionic thickener with ammonium hydroxide in a water solution to form a salt thereof, inert filler microspheres of an intermediate particle size, and inert filler particles of a small particle size, wherein the inert filler particles comprise diatomaceous earth, pyrogenic silica, or methylated silica. The grout excludes calcium hydroxide. | 2013-07-25 |
20130190437 | COATING AGENTS WITH GOOD STORAGE STABILITY, AND COATINGS PRODUCED THEREFROM WITH HIGH SCRATCH RESISTANCE AND SIMULTANEOUSLY GOOD WEATHERING RESISTANCE - Disclosed are coating compositions including (A) at least one member selected from hydroxyl-containing polyacrylate, polymethacrylate, polyurethane, polyester, polysiloxane, and combinations of two or more of the foregoing, (B) at least one compound having blocked isocyanate groups and having alkoxysilane groups, | 2013-07-25 |
20130190438 | DISPERSIONS OF SILICON NANOPARTICLES - Inorganic particle/polymer composites are described that involve chemical bonding between the elements of the composite. In some embodiments, the composite composition includes a polymer having side groups chemically bonded to inorganic particles. Furthermore, the composite composition can include chemically bonded inorganic particles and ordered copolymers. Various electrical, optical and electro-optical devices can be formed from the composites. | 2013-07-25 |
20130190439 | FLAME RESISTANT STYRENE BASED COMPOSITIONS COMPRISING ANTIMONY PENTOXIDE - The present invention relates to flame resistant vinyl aromatic polymer based compositions comprising,
| 2013-07-25 |
20130190440 | METHOD FOR PRODUCING POLYMER MOLDED ARTICLE, AND POLYMER MOLDED ARTICLE - Provided are a method for producing a polymer molded article, which is capable of increasing crystallinity, heat resistance, and isotropic elastic modulus while maintaining the original shape of a polymer molded body and a polymer molded article obtained by the method and having a high crystallinity, high heat resistance, and a high isotropic elastic modulus. The method for producing a polymer molded article includes the steps of: preparing a polymer material mainly containing a crystalline polymer; and impregnating the polymer material with a first gas having solubility in the crystalline polymer in an atmosphere in which the pressure of the first gas is equal to or higher than atmospheric pressure at a temperature higher than (Tm− | 2013-07-25 |
20130190441 | SPHERICAL, AMORPHOUS CALCIUM CARBONATE PARTICLES - Stabilized, spherical, amorphous calcium carbonate particles having a mean particle diameter in the range from 0.05 μm to 2.0 μm and a water content of at most 5.0 wt % measured as residual moisture at 200° C., wherein the calcium carbonate particles comprise at least one substance which has a molar mass greater than 100 g/mol and satisfies the formula R—X | 2013-07-25 |
20130190442 | LINEAR LOW DENSITY POLYETHYLENE NANOCOMPOSITE FIBERS AND METHOD OF MAKING THE SAME - The linear low density polyethylene nanocomposite fibers are formed from a linear low density polyethylene matrix having carbon nanotubes embedded therein. The addition of the carbon nanotubes enhances the overall toughness of the material, resulting in increases over conventional linear low density polyethylene in the material's tensile strength, elasticity and ductility. The carbon nanotubes constitute between about 0.08% and 1.0% by weight of the linear low density polyethylene nanocomposite fiber. Optimal toughness is found at about 0.3 wt %. The linear low density polyethylene nanocomposite fibers are made by first melting a quantity of linear low density polyethylene, and then blending a quantity of carbon nanotubes into the melted linear low density polyethylene to form a mixture, The mixture is then extruded to form the linear low density polyethylene nanocomposite fibers, which are then spun in a spinneret die to produce the finished linear low density polyethylene nanocomposite fibers. | 2013-07-25 |